demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID 19 hospitalized
COVID 19 hospitalizedCOVID 19 all comersCOVID-19 mild to moderateCOVID-19 severe or critically
potential COVID-19 treatments
adjuvant therapies
anticoagulant
anticoagulant, curative dose COALIZAO ACTION ATTACC, ACTIV-4a, and REMAP-CAP ... REMAP-CAP, ACTIV-4a, ATTACC ... COVID-PACT
anticoagulation, intermediate prophylactic dose INSPIRATION
heparin at therapeutic dose RAPID ...
anti-inflammatoty and immuno-therapy
anti-inflammatory therapies
anti GM-CSF
mavrilimumab MASH-COVID ...
clarithromycine Rashad ...
colchicine COLCOVID Salehzadeh GRECCO-19 RECOVERY ... Horby COL-COVID ...
Colchicine plus rosuvastatin Gaitan-Duarte ...
non-steroidal anti-inflammatory drugs
Indomethacin Ravichandran
stem cells Lanzoni Carmenate ... Shu Shi
corticosteroids
dexamethasone RECOVERY dexamethasone DEXA-COVID19 CODEX ... Jamaati
Dexamethasone 12mg COVID STEROID 2
Hydrocortisone CAPE-COVID Munch ...
methylprednisolone Tang X Metcovid Ranjbar Steroids-SARI
Immunostimulants drugs
convalescent plasma treatment ConCOVID ... ConPlas-19 COP-COVID-19 CONTAIN COVID-19 PC/COVID-19 NCT04397757 CONCOR-1 NCT04442191 DAWN-Plasma NCT04385199 COPLA-II trial NCT04403477 ... ASCOT RECOVERY ... CONFIDENT PERUCONPLASMA Bennett-Guerrero Salman Kirenga Co-CLARITY NCT04528368 Holm K CCAP-2 Baldeon Menichetti LIFESAVER Libster CP-COVID-19 Li Rasheed O’Donnell PlasmAr CAPSID AlQahtani REMAP-CAP ... RECOVER Pouladzadeh Sekine ...
Early convalescent plasma. Balcells
immunoglobulin therapy Sakoulas Tabarsi Raman
interferon
IFN beta-1a SOLIDARITY ... Darazam ... Kalil ...
high-dose IFN beta-1a Darazam
IFN beta-1b Rahmani Darazam ...
inhaled interferon
IFN alpha
pegylated interferon-α2b Pandit Shashi Bhushan
recombinant super-compound interferon rSIFN-co Li
SNG001 inhaled interferon beta Synairgen SG016
interferon / TFF2 Fu
peginterferon Jagannathan
PNB001 Lattmann
neutralizing antibody ITAC
amubarvimab/romlusevimab (BRII-196 and BRII-198-Brii Biosciences) ACTIV-3 ...
bamlanivimab monotherapy ACTIV-3/TICO LY-CoV555
casirivimab/imdevimab (Ronapreve) RECOVERY ... Somersan-Karakaya ...
cilgavimab and tixagevimab (Evusheld) ACTIV-3/TICO ...
equine polyclonal antibodies INM005 Lopardo
sotrovimab (Xevudy; VIR-7831) ACTIV-3/ TICO ...
Immunosuppressants drugs
adalimumab Fakharian
anakinra SAVE-MORE CORIMUNO-ANA-1
anti-interleukin-6
Levilimab V.Lomakin ...
sarilumab CORIMUNO-SARI-1 ... sarilumab Sanofi phase 3 outside US
sarilumab high dose (400mg) Lescure ...
sarilumab low dose (200mg) Lescure ...
tocilizumab Dongsheng Wang RCT-TCZ-COVID-19 EMPACTA RECOVERY Soin AS ... Rutgers NCT04412772 ... Declercq J ... NCT04577534 ... EU-CTR2020-001375-32 ... EU-CTR2020-001748-24 ... NCT04479358 ... NCT04434717 ... BACC Bay Tocilizumab Trial MARIPOSA COVACTA ... CORIMUNO-TOCI-1 ... REMAP-CAP ... Veiga Talaschian CORIMUNO-TOCI-ICU ... Rosas ...
canakinumab Sheng ... CAN-COVID
janus kinase (JAK) inhibitor
baricitinib COV-BARRIER ACTT-2 ... RECOVERY COV-BARRIER ...
ruxolitinib Cao
TD-0903
TD-0903 10mg Singh ...
TD-0903 1mg Singh ...
TD-0903 3mg Singh ...
tofacitinib STOP-COVID ...
lenzilumab LIVE-AIR ...
Kinase inhibitors
imatinib Aman
leflunomide Wang
antiandrogenic
progesterone Ghandehari
antiviral and associated therapy
azithromycin Sekhavati RECOVERY ... COALITION I Covid-19 Brazil ... Rashad A ... COALITION II Covid-19 Brazil ...
azvudine Ren
baloxavir marboxil Lou Y
bromhexine Li T
chloroquine and derivatives
chloroquine Huang
hydroxychloroquine HAHPS ORCHID RECOVERY SOLIDARITY ... Chen NO COVID-19 ... Abd-Elsalam TEACH HYCOVID Gonzalez ... NOR-Solidarity ... Coalition Covid-19 Brazil I ... FACCT Trial HYDRA ...
Emtricitabine/tenofovir plus colchicine plus rosuvastatin Gaitan-Duarte ...
Ensitrelvir (XOCOVA) Mukae - Phase 2a
favipiravir Udwadia AVIFAVIR Lou ... Chang Chen et al. NCT04310228-FAVI ... Dabbous HM FACCT Trial Udwadia AVIFAVIR NCT04542694 Ruzhentsova T Solaymani-Dodaran Shinkai
favipiravir plus interferon Khamis
hydroxychloroquine plus macrolides
azithromycin plus hydroxychloroquine ProPAC-COVID Coalition Covid-19 Brazil I ...
ivermectin Gonzalez ... Shahbaznejad Chaccour Kirti Krolewiecki I-TECH ... Galan Galan
ivermectin plus doxycycline Hashim A NCT04523831 ...
lopinavir/ritonavir RECOVERY SOLIDARITY ... Nojomi Ader ... ELACOI ... Cao REMAP-CAP ...
Lopinavir/ritonavir plus hydroxychloroquine REMAP-CAP ...
lopinavir/ritonavir plus interferon ß-1a Ader ...
lopinavir/ritonavir, ribavirin and interferon beta-1b Hung et al.
niclosamide Abdulamir
remdesivir NIH NIAID ACTT-1 DisCoVeRy ... SOLIDARITY ... Mahajan Norwegian NOR study ... Andreas ... GS-US-540-5774, 10 days GS-US-540-5774, 5 days GS-US-540-5773 ... CAP-China ...
sofosbuvir Alavi-moghaddam
sofosbuvir and daclatasvir Sadeghi Yakoot Mobarak S ...
sofosbuvir and ledipasvir Elgohary Nourian A
tenofovir/emtricitabine Gaitan-Duarte ...
umifenovir (arbidol) Nojomi ELACOI ... ELACOI ...
Drugs for acid related disorders
H2 blockers
famotidine Samimagham
miscellaneous
Aspirin RECOVERY ...
camostat mesilate Gunst JD
Cannabidiol Crippa ...
pyridostigmine Fragoso-Saavedra ...
sabizabulin VERU-111
Oral antidiabetic drugs
DPP-4 inhibitor Abuhasira
Renin-angiotensin-system-acting agents
angiotensin receptor blockers (ARBs) Nouri-Vaskeh
losartan University of Minnesota
discontinuation of ACEI/ARB Lopes ...
Vitamins
vitamin C Zhang
Vitamin D Entrenas ... Murai

74 studies excluded by filtering options 0

4909 Lee, 2004 010selection pending
4910 Soo, 2004 000selection pending
4911 HKU/UCH SARS Study Group, 2004 000selection pending
4912 Chan, 2003 000selection pending
4913 Beigel, 2018 010selection pending
5092 Yang, 2020 1133not a RCThigh risk of bias
5228 Bean, 2020 1193not a RCThigh risk of bias
5295 Zhang, 2020 1133not a RCThigh risk of bias
5331 Li, 2020 1134not a RCThigh risk of bias
5332 Meng, 2020 1134not a RCThigh risk of bias
5345 Yan et al., 2020 1204not a RCThigh risk of bias
5346 Mancia, 2020 1203not a RCThigh risk of bias
5347 Mehra, 2020 2124excludednot a RCThigh risk of bias
5348 Reynolds (COVID positive patient), 2020 1133not a RCThigh risk of bias
5349 Reynolds (prophylaxis), 2020 1133not a RCThigh risk of bias
5370 Khera (outpatients), 2020 1133not a RCThigh risk of bias
5372 Khera (inpatients), 2020 1133not a RCThigh risk of bias
5399 Northwell Consortium (Richardson), 2020 0990selection pending
5440 Morales, 2020 1130not a RCTrisk of bias not avaialble
5442 Mancia, 2020 000selection pending
5521 Del Amo, 2020 200excludedrisk of bias not avaialble
5532 Fosbøl, 2020 000selection pending
5604 Schneeweiss, 0 0130selection pending
5605 Vila-Corcole, 0 0130selection pending
5619 Pan, 2020 0130selection pending
5629 Fosbol, 2020 000selection pending
5797 Rossi, 0 0130selection pending
5903 Anzola, 2020 0100selection pending
6660 Bae, 2021 0120selection pending
6729 Shah, 2021 1133not a RCThigh risk of bias
6788 Waissengrin, 2021 0130selection pending
6790 Pawlowski, 2021 1130not a RCTrisk of bias not avaialble
6857 Anderson, 2020 000selection pending
6894 Andrejko, 2021 1200not a RCTrisk of bias not avaialble
6927 Rossman, 2021 0130selection pending
6931 Yair, 2921 1320not a RCTrisk of bias not avaialble
6934 Boyarsky, 2021 1320not a RCTrisk of bias not avaialble
6949 Pawlowski, 2021 1130not a RCTrisk of bias not avaialble
6981 Public Health England (Harris), 2021 1133not a RCThigh risk of bias
7025 Haberman, 2021 0130selection pending
7055 Shroff, 2021 000selection pending
7070 PHE variants (Technical briefing 12 22 may 2021), 2021 2202excludednot a RCT
7325 Skowronski, 2021 0130selection pending
7419 Scotland delta (Sheikh), 2021 1203not a RCThigh risk of bias
7420 PHE (Stowe), 2021 2133excludednot a RCThigh risk of bias
7940 Wall, 2021 000selection pending
7950 Harris, 2021 1133not a RCThigh risk of bias
8143 Butt, 2021 1202not a RCT
8147 Canada (Nasreen), 2021 1202not a RCT
8149 PHE Technical briefing 16 (11/18 June 2021), 2021 2133excludednot a RCThigh risk of bias
8150 Ramasamy, 2021 0320selection pending
8163 Israel delta press release, 0 100risk of bias not avaialble
8164 Public Health England, May 16, 2021 (Bernal), 2021 1202not a RCT
8255 REACT-SCOT, 2021 1200not a RCTrisk of bias not avaialble
8272 Martinez-Baz, 2021 1130not a RCTrisk of bias not avaialble
8274 REACT-1 round 13 final report (Elliott, Imperial College London), 2021 1133not a RCThigh risk of bias
8275 Musser, 2021 2130excludednot a RCTrisk of bias not avaialble
8294 CDC Mesa County, Colorado, 2021 1133not a RCThigh risk of bias
8313 Bahl (Fully vaccinated vs unvaccinated), 2021 0100selection pending
8350 Rosenberg, 2021 2130excludednot a RCTrisk of bias not avaialble
8359 Oxford (Pouwels), 2021 1132not a RCT
8360 HEROES-RECOVER (Fowlkes), 2021 1133not a RCThigh risk of bias
8513 Grannis, 2021 1203not a RCThigh risk of bias
8514 VA (Bajema), 2021 1203not a RCThigh risk of bias
8515 Scobie, 2021 2200excludednot a RCTrisk of bias not avaialble
9170 UKHSA report 33 (23 december 2021), 2021 2200excludednot a RCTrisk of bias not avaialble
9176 UKHSA 31 december 2021, 2021 2200excludednot a RCTrisk of bias not avaialble
9214 Southern California (Lewnard), 2022 2130excludednot a RCTrisk of bias not avaialble
9216 Sultan, 2022 0120selection pending
9224 Reynolds, 2022 000selection pending
9267 Ostropolets, 2021 0120selection pending
9294 UKHSA (report W4- 27 January), 2022 2120excludednot a RCTrisk of bias not avaialble
9491 Li X, 2022 1120not a RCTrisk of bias not avaialble
9590 UKHSA report week 12 (24 March 2022), 2022 1120not a RCTrisk of bias not avaialble